Calendario›SNY›Nirsevimab Respiratory…

Nirsevimab Respiratory…

RSV Immunisation Status in Queensland (Australia)

Ensayo de Sanofi en RSV Immunization (del registro, en inglés).

Fase

no aplica

Estado

Reclutando pacientes

Participantes

1.200

previstos

Centros

1

Fin del objetivo primario

ago 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en may 2026.

Qué mide

The proportion of immunised infants among all enrolled infants (March 2026-May 2026) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia. The study will focus on: 1\. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland. Secondary objectives of this study are as follows: 1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab. 1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation. 2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact. 2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland. 3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.

Más ensayos de SNY

Todos los de SNY, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07615192), actualizada en jul 2026.